Ronco Troels, Aragao Maria F, Svenningsen Søren, Christensen Jørn B, Permin Anders, Saaby Lasse, Bionda Nina, Lantz Ellen E, Olsen Rikke H
Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Department of Chemistry, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.
JAC Antimicrob Resist. 2021 Jul 29;3(3):dlab108. doi: 10.1093/jacamr/dlab108. eCollection 2021 Sep.
Bacterial biofilm formation is a complicating factor in the antimicrobial treatment of bacterial infections.
In this study, we assessed the impact of a novel hydrogel with the active antimicrobial compound JBC 1847 on eradication of preformed biofilms of , and MRSA , and evaluated the efficacy of MRSA wound treatment.
Biofilms were exposed to JBC 1847 for 24 h and subsequently the treatments were neutralized and surviving biofilm-associated bacteria recovered and enumerated. The efficacy of the hydrogel on post-treatment load of MRSA was determined in a murine model of MRSA wound infection, and skin samples of the infected mice were examined histologically to evaluate the degree of healing.
A concentration-dependent eradication of biofilm-embedded bacteria by JBC 1847 was observed for all three pathogens, and the hydrogel caused a greater than four log reduction of cfu in all cases. In the mouse model, treatment with the hydrogel significantly reduced the cfu/mL of MRSA compared with treatment of MRSA-infected wounds with pure hydrogel. Histopathological analysis of the wounds showed that the JBC 1847 treatment group had a lower grade of inflammation, a higher mean score of re-epithelization and higher mean scores of parameters assessing the maturity of the newly formed epidermis, compared with both the fusidic acid 2% and vehicle treatment groups.
The novel hydrogel shows promising results as a candidate for future wound treatment, likely to be highly effective even in the case of biofilm-complicating infected wounds.
细菌生物膜的形成是细菌感染抗菌治疗中的一个复杂因素。
在本研究中，我们评估了含有活性抗菌化合物JBC 1847的新型水凝胶对根除大肠杆菌、金黄色葡萄球菌和耐甲氧西林金黄色葡萄球菌（MRSA）预先形成的生物膜的影响，并评估了其对MRSA伤口治疗的效果。
将生物膜暴露于JBC 1847中24小时，随后中和处理，回收并计数存活的生物膜相关细菌。在MRSA伤口感染的小鼠模型中测定水凝胶对MRSA治疗后负荷的效果，并对感染小鼠的皮肤样本进行组织学检查以评估愈合程度。
对于所有三种病原体，均观察到JBC 1847对生物膜包埋细菌的浓度依赖性根除，并且在所有情况下水凝胶均使菌落形成单位（cfu）减少超过四个对数。在小鼠模型中，与用纯水凝胶治疗MRSA感染伤口相比，用水凝胶治疗可显著降低MRSA的cfu/mL。伤口的组织病理学分析表明，与2%夫西地酸治疗组和赋形剂治疗组相比，JBC 1847治疗组的炎症等级较低，再上皮化平均得分较高，评估新形成表皮成熟度的参数平均得分也较高。
这种新型水凝胶作为未来伤口治疗的候选药物显示出有前景的结果，即使在生物膜复杂的感染伤口情况下也可能非常有效。
